Ilmarinen Mutual Pension Insurance Co lifted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 21.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 258,000 shares of the medical equipment provider’s stock after purchasing an additional 45,000 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Boston Scientific were worth $11,262,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. boosted its position in Boston Scientific by 106.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 927 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 478 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its holdings in Boston Scientific by 2,801.4% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 15,000 shares of the medical equipment provider’s stock valued at $655,000 after purchasing an additional 14,483 shares during the period. Castlefield Investment Partners LLP grew its holdings in Boston Scientific by 18.7% in the third quarter. Castlefield Investment Partners LLP now owns 67,559 shares of the medical equipment provider’s stock valued at $2,949,000 after purchasing an additional 10,652 shares during the period. Saranac Partners Ltd grew its holdings in Boston Scientific by 4.4% in the third quarter. Saranac Partners Ltd now owns 156,913 shares of the medical equipment provider’s stock valued at $6,584,000 after purchasing an additional 6,648 shares during the period. Finally, Advisors Asset Management Inc. purchased a new stake in shares of Boston Scientific in the third quarter valued at approximately $2,120,000. Institutional investors and hedge funds own 89.07% of the company’s stock.
Analyst Ratings Changes
BSX has been the subject of several research analyst reports. Citigroup reduced their target price on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, October 29th. Truist Financial dropped their price target on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. Needham & Company LLC dropped their price target on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, October 28th. Stifel Nicolaus cut their price target on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a report on Monday, October 26th. Finally, Deutsche Bank set a $48.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $61.43.
Get Our Latest Stock Analysis on Boston Scientific
Boston Scientific Stock Down 2.4%
NYSE BSX opened at $41.96 on Friday. The business has a fifty day moving average price of $43.83 and a 200 day moving average price of $53.26. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. The company has a market cap of $60.82 billion, a P/E ratio of 17.78, a P/E/G ratio of 1.29 and a beta of 0.60. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $101.91.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the previous year, the company posted $0.75 EPS. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts anticipate that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.
Boston Scientific Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Further Reading
- Five stocks we like better than Boston Scientific
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
